Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/29/23
End: 06/15/26
Due: 06/15/27
Phase: N/A
Priority: Normal
Start: 01/01/25
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 09/30/25
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 01/27/22
End: 01/24/25
Due: 01/24/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes | NCT05949281 | Asger Lund, MD | user2@example.com | None | 2023-08-29 | 2026-06-15 | 2027-06-15 | - | - | 2025-07-14 |
| The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes | NCT06881472 | Asger Lund, MD | user2@example.com | None | 2025-01-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Treatment of Bile Acid Diarrhoea With Atorvastatin | NCT07042165 | Asger Lund, MD | user2@example.com | None | 2025-09-30 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |
| The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | NCT05078255 | Asger Lund, MD | user2@example.com | None | 2022-01-27 | 2025-01-24 | 2026-01-24 | - | - | 2025-07-14 |